HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
暂无分享,去创建一个
Stephen Fox | Sue Healey | Brent Reynolds | Georgia Chenevix-Trench | Rosemary L Balleine | Kum Kum Khanna | Alexander Dobrovic | Sunil R Lakhani | S. Fox | A. Vargas | S. Lakhani | N. Waddell | G. Chenevix-Trench | J. Beesley | R. Balleine | M. Cummings | K. Khanna | N. Kurniawan | H. Do | A. Dobrovic | P. Simpson | C. Smart | M. Franco | S. Parry | L. Reid | A. Lane | S. Cocciardi | M. Bilous | S. Healey | P. Keith | Suzanne Parry | Jonathan Beesley | Nyoman Kurniawan | Ana Cristina Vargas | A. Skálová | B. Reynolds | Nic Waddell | Sibylle Cocciardi | Lynne Reid | Patricia Keith | Hongdo Do | Annette Lane | Alena Skalova | Chanel E Smart | Peter T Simpson | Margaret Cummings | Michael Bilous | B. J. Morrison | Leonard M Da Silva | Leonard Da Silva | Brian J Morrison | Pria Pakkiri | Paulo Faria | Emilio Pereira | Marcello Franco | P. Pakkiri | L. D. Da Silva | E. Pereira | P. Faria | A. Skalova
[1] N. Wigler,et al. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. , 2004, European journal of cancer.
[2] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[3] D. Feldser,et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.
[4] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[5] S. Steinberg,et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.
[6] D. Easton,et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.
[7] C. Perou,et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.
[8] A. Stan,et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer , 2007, Modern Pathology.
[9] J. Krupiński,et al. Hyaluronan expression following middle cerebral artery occlusion in the rat , 2006, Neuroreport.
[10] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[12] W. Gerald,et al. Genes that mediate breast cancer metastasis to the brain , 2009, Nature.
[13] Keith L. Ligon,et al. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.
[14] S. Paik,et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 , 2007 .
[15] Y. Yarden,et al. Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[16] Carmen Behrens,et al. HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors , 2009, Clinical Cancer Research.
[17] S. Gabriel,et al. High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.
[18] I. Ellis,et al. The influence of basal phenotype on the metastatic pattern of breast cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).
[19] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[20] Jian-Bing Fan,et al. A versatile assay for high-throughput gene expression profiling on universal array matrices. , 2004, Genome research.
[21] Carlos L Arteaga,et al. ErbB-targeted therapeutic approaches in human cancer. , 2003, Experimental cell research.
[22] A. Nandi,et al. Hyaluronan Anchoring and Regulation on the Surface of Vascular Endothelial Cells Is Mediated through the Functionally Active Form of CD44* , 2000, The Journal of Biological Chemistry.
[23] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[24] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[25] B. Ford,et al. Neuregulin expression after focal stroke in the rat , 2002, Neuroscience Letters.
[26] G. Semenza,et al. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. , 1993, The Journal of biological chemistry.
[27] W. Gerald,et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.
[28] M. Lemmon,et al. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface , 2004, FEBS letters.
[29] Paul J. Harrison,et al. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain , 2004, Neuroscience.
[30] M. Loda,et al. Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.
[31] J. Montero,et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Meijer,et al. A Fast, Sensitive and Accurate High Resolution Melting (HRM) Technology-Based Assay to Screen for Common K-ras Mutations , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[33] N. Lin. Primary Breast Cancer Phenotypes Associated With Propensity for Central Nervous System Metastases , 2007 .
[34] S. Fox,et al. HER 3 and downstream pathways are involved in colonization of brain metastases from breast cancer , 2010 .
[35] David M. Thomas,et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer , 2006, BMC Cancer.
[36] Thomas D. Wu,et al. Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes , 2009, Molecular Cancer Research.
[37] Jian-Bing Fan,et al. Tumorigenesis and Neoplastic Progression Quantitative Gene Expression Profiling in Formalin-Fixed , Paraffin-Embedded Tissues Using Universal Bead Arrays , 2004 .
[38] Sabine Tejpar,et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.
[39] R. Weil,et al. Breast cancer metastasis to the central nervous system. , 2005, The American journal of pathology.
[40] Ian O Ellis,et al. Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Raymond R Tubbs,et al. Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.
[42] Lillian S Kao,et al. Analysis of variance: is there a difference in means and what does it mean? , 2008, The Journal of surgical research.
[43] M. Ringnér,et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.
[44] Philip A. Romero,et al. Exploring protein fitness landscapes by directed evolution , 2009, Nature Reviews Molecular Cell Biology.
[45] Hans Clevers,et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines , 2010, Breast Cancer Research and Treatment.
[46] N. Hynes,et al. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. , 2009, Cancer cell.
[47] M. Sliwkowski,et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.
[48] S. Hilsenbeck,et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases , 2006, Cancer.
[49] M. Poupon,et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts , 2009, British Journal of Cancer.
[50] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[51] G. Parmigiani,et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. , 2007, Genome research.
[52] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[53] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[54] S. Lakhani,et al. Aberrant Expression of E-cadherin in Lobular Carcinomas of the Breast , 2008, The American journal of surgical pathology.
[55] R. Cardiff,et al. Active signaling by Neu in transgenic mice , 1998, Oncogene.
[56] Peter Devilee,et al. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .
[57] M. Berger,et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.
[58] E. Winer,et al. CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.